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Abstract: Osteoporotic fractures are associated with significant morbidity, reduced quality of 
life, increased mortality, and high health care costs. Bisphosphonates are standard therapy for 
treatment of osteoporosis. However, patient compliance and persistence with oral weekly or 
monthly bisphosphonate therapy are suboptimal and may lead to reduced effectiveness. 
  Zoledronic acid (ZOL) is an intravenous bisphosphonate that is given once yearly for the treat-
ment of osteoporosis via a medically supervised 15-minute infusion. This ensures compliance 
for a full 12 months. In clinical trials, an annual infusion of ZOL 5 mg has shown sustained 
efficacy in reducing hip and spine fractures in postmenopausal women with osteoporosis. It has 
also been shown to increase bone density in postmenopausal women with osteopenia (low 
bone mass) and in men with osteoporosis. Transient flu-like symptoms are the most common 
adverse effects following ZOL infusion, and these can generally be managed with   acetaminophen. 
The availability of an intravenous bisphosphonate that ensures compliance over a long dosing 
interval may help to overcome barriers to efficacy resulting from poor long-term compliance 
with oral agents.
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Introduction
Osteoporosis affects an estimated 75 million persons in Europe, the United States, 
and Japan1 and is associated with an estimated 9 million new fractures every year 
worldwide,1 including more than 2 million fractures per year in the United States.2 
Osteoporosis-related fractures are associated with significant morbidity, increased 
mortality, and enormous financial costs.3
Oral nitrogen-containing bisphosphonates (eg, alendronate, risedronate, and iban-
dronate) are the standard of care in osteoporosis.4 These bone-specific agents inhibit 
farnesyl diphosphate synthase, a key branch point of the mevalonate pathway, and 
thus, inhibit protein prenylation in osteoclasts.5 This activity makes bisphosphonates 
potent inhibitors of bone resorption and remodeling activity.6 Oral bisphosphonates 
have been shown to increase bone mineral density (BMD) and reduce fracture risk. 
However, the “real world” effectiveness of oral treatment is compromised by subop-
timal patient compliance and persistence with prescribed regimens.7–11
Zoledronic acid (ZOL) is an intravenous, nitrogen-containing bisphosphonate with 
a prolonged dosing interval, a characteristic that has the potential to increase patient 
compliance with bisphosphonate therapy and thereby to improve patient outcomes. 
ZOL 5 mg currently is approved by the Food and Drug Administration for the treat-
ment of postmenopausal osteoporosis, treatment of male osteoporosis, and treatment International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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and prevention of glucocorticoid-induced osteoporosis as a 
once-yearly infusion. It is also approved for prevention of 
osteoporosis in postmenopausal women as an infusion given 
once every 2 years.12
Osteoporosis: a pervasive problem
Although the population of individuals with identified 
  osteoporosis is quite large, it is also clear that these conditions 
are underdiagnosed and undertreated.13–15 For example, the 
IMPACT study reported in 2005 that re-evaluation of routine 
spine X-rays of postmenopausal women aged 65–80 years 
resulted in lack of reporting of vertebral fracture findings for 
45.2% of X-rays in North America, 46.5% in South America, 
and 29.5% in Europe/South Africa/Australia.13
The prevalence of osteoporosis increases with age; 
  overall, it is estimated that 1 in 2 women and 1 in 4 men aged 
more than 50 years will have an osteoporosis-related fracture 
in their remaining lifetime.16 The aging of the world’s popula-
tion is accompanied by a resultant marked increase in the 
projected overall prevalence and cost of osteoporosis-related 
fractures.2,17 Thus, in the United States, eg, it is estimated 
that the number of women and men with osteopenia/ 
osteoporosis will increase from 44 million to more than 
61 million by 202016,18 and that by 2025, annual fractures 
and associated costs in the United States will increase by 
nearly 50%.2 Likewise, worldwide projections of the inci-
dence of hip fracture indicate that it will increase by 240% 
in women and 310% in men between 1990 and 2050.19
The primary health burden imposed by osteoporosis is 
increased risk for bone fractures and their sequelae.20   Fractures 
are associated with disability, reduced quality of life, increased 
risk of subsequent fracture, increased   mortality, and high health 
care costs.1–3,21–23 In the United States, costs of   osteoporosis- 
related fractures were estimated at $19 billion for 2005 and 
are expected to increase to 25.3 billion by 2025.16 In the 
European Union, osteoporosis-related fractures now costs 
more than €48 billion per year for hospital health care alone,3 
and disability associated with osteoporosis is greater than 
that associated with cancers, excluding lung cancer, and 
comparable with that associated with rheumatoid arthritis, 
asthma, and hypertension-related heart disease.1 In European 
women aged 45 years and above, osteoporosis accounts for 
more days spent in the hospital than diseases such as diabetes, 
myocardial infarction, or breast cancer.1 It has been reported 
that 26% of patients suffer another fracture in the year fol-
lowing a vertebral fracture,23 and it is estimated that 24% of 
patients aged more than 50 years with a hip fracture die from 
fracture-related complications during the following year.16
Diagnosis
BMD correlates with bone strength and predicts fracture risk. 
BMD measurements by means of dual-energy X-ray absorp-
tiometry scans of the hip and spine are used as the primary 
basis for the diagnosis of osteoporosis. The World Health 
Organization (WHO) defines osteoporosis in men and women 
as a BMD of 2.5 or more standard deviations (SD) below 
that of a young normal adult (T-score of −2.5 or lower); 
osteopenia, or low bone mass, as a BMD between 1.0 and 
2.5 SD below that of a young normal adult (T-score 
between −1.0 and −2.5); and normal BMD as within 1 SD 
of the reference value for a young normal adult (T-score 
of −1.0 or higher). The presence of a low-trauma fracture is 
also sufficient for the diagnosis of osteoporosis in patients 
with T-scores between −1.0 and −2.5.
Treatment decisions for patients with osteopenia should 
be made based on overall fracture risk. The WHO has devel-
oped an Internet-based fracture risk assessment tool 
(FRAX).24 FRAX allows the user to predict the 10-year 
probability of a hip or other major osteoporotic fracture 
(clinical spine, wrist, and proximal humerus) on the basis of 
femoral neck BMD and other risk factors (age, gender, weight 
and height, personal history of fracture, parental history of 
hip fracture, smoking, glucocorticoid use, presence of rheu-
matoid arthritis, presence of secondary osteoporosis, and 
alcohol consumption).   Figure 1 shows a sample FRAX 
  calculation. The FRAX tool is free and can be accessed at 
http://www.shef.ac.uk/FRAX.
Treatment recommendations
Osteoporosis is undertreated, even in patients with the most 
advanced disease – ie, those who have the highest risk of 
fracture and are the most important target population for 
pharmacologic intervention. For example, a recent National 
Health and Nutrition Examination Survey (NHANES) study 
indicated that antiresorptive medication was being taken by 
only 17% of women aged more than 65 years who had sus-
tained a prior fracture after 50 years of age.14 An earlier study 
based on Medicare claims between 1995 and 2004 and 
involving more than 15,000 patients with hip fracture aged 
65 years or more showed that the percentage of patients 
receiving osteoporosis treatment within 6 months after frac-
ture reached a high of only 31% in 2002 and remained stable 
thereafter.25
According to the 2008 National Osteoporosis Foundation 
guidelines,26 treatment should be considered in postmeno-
pausal women and men aged more than 50 years, who present 
with any one of the following:International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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1.  Hip or vertebral (clinical or morphometric) fracture
2.  T-score of #−2.5 at the femoral neck or spine after 
appropriate evaluation to exclude secondary causes
3.  Low bone mass and a 10-year probability of hip fracture 
of $3%  or  a  10-year  probability  of  any  major 
  osteoporosis-related fracture of $20% based on the 
FRAX calculation
Poor compliance with oral therapies
Poor compliance and persistence limit the effectiveness of 
current osteoporosis therapies. It has been found that approxi-
mately 50% of patients fail to comply or persist with osteo-
porosis therapy within the first year of treatment, and that 
poor compliance is associated with higher fracture rates and 
increased morbidity, mortality, and health care costs.7–11,27,28 
Compliance is particularly problematic for patients aged 
65 years and above, who are more likely to have cognitive 
impairment and polypharmacy issues. Weekly and monthly 
regimens introduced for the past several years may have 
produced modest improvements compared with daily regi-
mens in compliance and persistence, but rates nevertheless 
remain suboptimal.29–31
The most commonly prescribed oral bisphosphonates 
must be taken in the morning on an empty stomach with 6–8 
ounces of plain water, and the patient must not ingest food 
or beverages other than water for 30–60 minutes after 
  administration, since these can significantly reduce   absorption. 
The patient must also remain sitting or standing upright for 
30–60 minutes after ingestion in order to avoid upper 
 gastrointestinal irritation. It has been shown in one study that 
25% of patients disregarded at least one dosing requirement 
despite detailed instructions from health care providers.32
In addition to the well-established absorption issues asso-
ciated with beverages such as juice or coffee, it has become 
apparent that plain drinking water can also be problematic 
under some circumstances. Calcium ingestion at the time of 
bisphosphonate administration can inhibit absorption,33 and 
it has been found that the calcium concentration of waters 
(tap and bottled) across the United States and Canada range 
from 1 to 135 mg/L,34 with some water having enough calcium 
to potentially interfere with bisphosphonate absorption.
ZOL 5 mg: an intravenous 
bisphosphonate for the prevention 
and treatment of osteoporosis
Increased compliance and persistence with bisphosphonate 
treatment could improve patient outcomes and reduce the 
social and economic burdens of osteoporosis. The ability to 
provide a medically supervised dose of a bisphosphonate 
ensures compliance and persistence for the duration of the 
dosing interval. Intravenously administered ZOL circulates 
for approximately 24 hours and rapidly binds to bone. Any 
drug that is not bound to bone is excreted through the kidneys. 
The prolonged duration of action of ZOL is due to its high 
binding affinity to bone mineral.12
Country: US (Caucasian) Name/ID:
Questionnaire:
1. Age (between 40–90 years) or Date of birth
2. Sex
3. Weight (kg)
4. Height (cm)
5. Previous fracture
6. Parent fractured hip
7. Current smoking
8. Glucocorticoids
9. Rheumatoid arthritis
Age: Date of birth:
Y: M: D:
Male Female
No Yes
No Yes
No Yes
No Yes
No Yes
10. Secondary osteoporosis
11. Alcohol 3 more units per day
12. Femoral neck BMD (g/cm2)
No Yes
No Yes
T-score: –2.4
Clear Calculate
74
Major osteoporotic
Hip fracture
21
10
BMI 23.2
The ten year probability of fracture (%)
with BMD
67
170
About the risk factors
GE-Lunar .71
Figure 1 example of a fracture risk calculation using FRAX, a Web-based fracture risk assessment tool (available at: http://www.shef.ac.uk/FRAX).
Abbreviations: BMD, bone mineral density; BMI, body mass index.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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The Health Outcomes and Reduced Incidence with 
  Zoledronic acid Once Yearly (HORIZON) clinical trial pro-
gram has included studies of ZOL in postmenopausal women 
with osteoporosis, men and women with hip fracture, men with 
osteoporosis, and postmenopausal women with osteopenia.
Efficacy in treating osteoporosis  
in the HORIZON trials
Postmenopausal women with osteoporosis
In the HORIZON-Pivotal Fracture Trial (HORIZON-PFT), 
postmenopausal women with osteoporosis were randomized 
to receive a 15-minute infusion of ZOL 5 mg (n = 3,889) or 
placebo (n = 3,876) at baseline, 12 months, and 24 months 
and were followed for 3 years.35 At 3 years, compared with 
placebo, ZOL 5 mg reduced risk of morphometric vertebral 
fracture by 70% (3.3% vs 10.9%, P , 0.0001), risk of hip 
fracture by 41% (1.4% vs 2.5%, P = 0.002), risk of nonver-
tebral fractures by 25% (8.0% vs 10.7%, P , 0.001), and 
risk of clinical vertebral fractures by 77% (0.5% vs 2.6%, 
P , 0.001) (Figure 2). ZOL significantly increased BMD at 
the total hip (6.0%), lumbar spine (6.7%), and femoral neck 
(5.1%) compared with placebo (P , 0.001 for all   comparisons). 
Thus, ZOL was shown to be effective over a 3-year period 
in preventing fractures and increasing bone mass at key 
skeletal sites in postmenopausal women.
Women and men with hip fracture
In the HORIZON-Recurrent Fracture Trial   (HORIZON-RFT), 
women and men more than 50 years of age who had suffered 
a recent hip fracture were randomized to receive annual 
  infusions of ZOL 5 mg (n = 1,065) or placebo (n = 1,062) 
within 90 days after hip fracture repair.36 The trial was event-
driven, with the stopping point determined by occurrence of 
a prespecified number of fracture events. The median 
  follow-up duration was 1.9 years. Compared with placebo, 
ZOL 5 mg reduced the rate of new clinical fractures and 
clinical vertebral fractures by 35% (8.6% vs 13.9%, P = 0.001) 
and 46% (1.7% vs 3.8%, P = 0.02), respectively (Figure 3). 
Total hip BMD increased in the ZOL group by 2.6%, 4.7%, 
and 5.5% at 12, 24, and 36 months and decreased in the pla-
cebo group by 1.0%, 0.7%, and 0.9%, respectively (P , 0.001 
for all comparisons). HORIZON-RFT demonstrated that 
ZOL was effective in preventing secondary fractures and 
increasing bone mass in this high-risk patient population.
Men with osteoporosis
In the HORIZON Male trial, 302 men with osteoporosis aged 
25–85 years were randomized to receive an annual infusion 
of ZOL 5 mg or oral alendronate 70 mg weekly.37 The primary 
efficacy end point was change in BMD from baseline over 
2 years. The results showed an increase in lumbar spine BMD 
of 6.1% in the ZOL treatment group and 6.2% in the alen-
dronate group (nonsignificant difference). This led to the 
approval of ZOL for men with osteoporosis.
Efficacy in prevention of osteoporosis
Although patients diagnosed with osteoporosis have the 
highest fracture risk, patients with osteopenia also sustain 
fractures.20,38 In the National Osteoporosis Risk Assessment 
(NORA) study, which measured peripheral bone density in 
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Figure 2 Cumulative 3-year fracture incidence in postmenopausal women with osteoporosis receiving once-yearly ZOL 5 mg or placebo in HORIZON-PFT.
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more than 200,000 postmenopausal women aged 50 years 
or above with no prior osteoporosis diagnosis, 39.6% had 
osteopenia and 7.2% had osteoporosis on the basis of 
T-scores.38 For women with T-scores diagnostic of   osteopenia, 
the relative risk of developing clinical fractures within the 
first 12 months of follow-up was 1.73 (95% confidence 
interval, 1.57–1.91).38 These findings indicate that although 
low BMD is a clear risk factor for future fracture, other risk 
factors play a role, and BMD should not be the sole deter-
minant in risk assessment.20,39,40 As noted earlier, the National 
Osteoporosis Foundation recommends treatment for patients 
with low bone mass (BMD T-score between −1.0 and −2.5) 
and a 10-year probability of hip fracture of $3%, or of any 
major osteoporosis-related fracture of $20%, based on the 
FRAX calculation.26
ZOL has also been shown to increase bone mass in post-
menopausal women with osteopenia. In the HORIZON 
Prevention trial, 581 postmenopausal women with osteopenia 
(BMD T-scores between −1.0 and −2.5 at the lumbar spine 
and greater than −2.5 at the femoral neck) were randomized 
to receive an infusion of ZOL 5 mg at baseline and at 1 year 
(once-yearly administration), an infusion of ZOL at baseline 
and a placebo infusion at 1 year (administration once every 
2 years), or a placebo infusion at baseline and at 1 year.41 
The change in lumbar spine BMD at 2 years, the primary 
endpoint of the trial, was +5.18% with yearly ZOL 
and +4.42% with ZOL once every 2 years, compared with a 
loss of 1.32% in the placebo group (P , 0.001 for both 
comparisons) (Figure 4). Significantly greater increases for 
both ZOL regimens vs placebo were also observed in lumbar 
spine BMD at 12 months and at proximal femur sites (total hip, 
femoral neck, and trochanter) at both 12 and 24 months 
(P , 0.001 for all comparisons). Thus, ZOL given once every 
2 years was effective in preventing bone loss in postmeno-
pausal women with low bone mass.
ZOL administered every 2 years is currently approved 
for prevention of osteoporosis. However, once-yearly admin-
istration of ZOL could also be considered for patients with 
BMD T-scores approaching −2.5 (the diagnostic cutoff point 
for osteoporosis) and a FRAX score indicating a 10-year risk 
of .20% for major osteoporotic fracture and/or $3% for 
hip fracture. This decision, however, must be made by the 
physician on a case-by-case basis.
Safety and tolerability of ZOL  
and potential bisphosphonate safety issues
ZOL 5 mg infusions have been well tolerated in clinical trials. 
Postdose symptoms (eg, pyrexia, myalgia, headache, flu-like 
symptoms, and arthralgia) were the most commonly reported 
adverse events but were generally mild and transient. These 
symptoms tended to occur within 3 days of infusion and 
resolve within 3 days of onset (although resolution could 
take up to 14 days), and they were effectively managed with 
over-the-counter anti-inflammatory analgesics such as 
acetaminophen.12,35–37
Renal effects
HORIZON-PFT included monitoring of renal effects in more 
than 5,000 patients after each study infusion.35 Transient 
serum creatinine increases were reported in 1.8% of ZOL 
patients and 0.8% of placebo patients within 10 days of 
  dosing, and in all cases resolved without specific therapy.12 
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No differences in long-term renal effects were observed more 
than 3 years between ZOL and placebo. ZOL should not 
be used in patients with impaired renal function (creatinine 
clearance ,35 mL/min). ZOL should be administered over 
at least 15 minutes, and patients should be appropriately 
hydrated prior to administration.
Osteonecrosis of the jaw
Osteonecrosis of the jaw (ONJ) has been observed primarily 
in patients with multiple myeloma or metastatic cancer of 
the bone receiving IV bisphosphonates, with the majority of 
cases preceded by dental surgical procedures.42 A review 
published in 2007 indicates that there is a very low risk of 
ONJ in patients receiving oral bisphosphonates for osteopo-
rosis (between 1 in 10,000 and ,1 in 100,000 patient-
treatment years).43 There were no spontaneous reports of 
ONJ in ZOL clinical trials. A search of the HORIZON-PFT 
adverse event database identified potential cases of ONJ in 
1 ZOL patient and 1 placebo patient. Both patients experi-
enced delayed healing, and both cases resolved with antibiot-
ics and/or debridement.35
Hypocalcemia
A low incidence of hypocalcemia (,7.5 mg/dL; ∼0.2%) was 
observed in HORIZON-PFT, and no treatment-emergent 
cases were reported in HORIZON-RFT.12
Atrial fibrillation
In HORIZON-PFT, the overall incidence of all atrial fibril-
lation events was similar to ZOL and placebo, but more of 
these events resulted in hospitalization in the ZOL group 
(1.3%) than in the placebo group (0.5%) and were classified 
as serious adverse events.35 The majority of these events 
occurred more than 30 days after infusion, when active drug 
would be absent from the systemic circulation. Moreover, 
an electrocardiography substudy in 559 patients evaluated 
prior to and 9 to 11 days after the third infusion showed no 
significant difference in prevalence of atrial fibrillation in 
the ZOL group (2.1%) vs the placebo group (2.8%). In 
HORIZON-RFT, serious atrial fibrillation events occurred 
in 1.1% of ZOL patients and 1.3% of placebo patients (no 
significant difference). Preclinical and other clinical trials of 
ZOL have suggested no association between this agent and 
atrial fibrillation.36
Oversuppression of bone remodeling  
and atypical fractures
As clinical experience with patients on bisphosphonate 
therapy has accumulated, case reports have emerged of 
subtrochanteric or femoral shaft fractures in patients on long-
term treatment (usually .4 years). Some of these fractures 
have exhibited characteristics that are atypical of osteoporotic 
fracture (eg, transverse rather than spiral; preceded by thigh 
pain for weeks or months; bilateral; and associated with thick 
rather than thin bone cortices).44–48 Concerns have been raised 
that these fractures may be associated with long-term sup-
pression of bone remodeling, resulting in stress fractures that 
do not heal. However, more information needs to be collected 
and evaluated in order to understand the cause of these 
fractures.
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Appropriate prescribing  
and administration of ZOL 5 mg
The following are key aspects of appropriate prescribing and 
administration of ZOL 5 mg for prevention and treatment of 
osteoporosis:
1.  Patients who are taking oral bisphosphonates can be safely 
switched to ZOL 5 mg. In a study in 225 postmenopausal 
women who had been on oral alendronate therapy for at 
least 1 year, a single infusion of ZOL 5 mg maintained 
lumbar spine BMD at 1 year and had a safety profile 
similar to that of weekly oral alendronate 70 mg.49
2.  Patients should have an adequate daily intake of calcium 
and vitamin D: 1,200 mg elemental calcium and 800–
1,000 IU vitamin D.12,26
3.  Preexisting hypocalcemia and disturbances of mineral 
metabolism (eg, those associated with hypoparathyroid-
ism, thyroid surgery, parathyroid surgery, malabsorption 
syndromes, or excision of small intestine) must be effec-
tively treated before initiating therapy with ZOL.
4.  Patients should drink at least 2 glasses of fluid within a 
few hours before receiving a ZOL 5 mg infusion.
5.  ZOL should not be used in patients with impaired renal 
function (creatinine clearance ,35 mL/min).
6.  ZOL 5 mg infusion should be given over at least 15   minutes 
at a constant infusion rate.
7.  Administration of acetaminophen following ZOL 5 mg 
administration may help reduce the incidence of postdose 
reaction symptoms.
8.  For patients diagnosed with osteoporosis, once-yearly 
ZOL infusion may be prescribed.
9.  For patients diagnosed with osteopenia and with low 
fracture risk according to FRAX, ZOL infusion every 
2 years may be prescribed; for patients diagnosed with 
osteopenia and high fracture risk according to FRAX, 
once-yearly ZOL infusion may be considered.
A new approach to the prevention 
and treatment of osteoporosis
The availability of ZOL 5 mg as a once-yearly or once-every-
2-years infusion offers a new approach to treatment and pre-
vention of osteoporosis. ZOL has proven antifracture efficacy 
at key skeletal sites in placebo-controlled trials. Although there 
have not been any head-to-head trials comparing oral bispho-
sphonates with ZOL that provided fracture outcome data, ZOL 
has been shown to provide comparable efficacy to alendronate 
with respect to BMD gains.37 Use of ZOL typically requires 
a separate appointment for administration of the infusion; 
however, by guaranteeing compliance for the duration of its 
prolonged dosing interval, ZOL potentially removes barriers 
to optimal therapeutic outcomes.
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